口服抗凝剂治疗的多益作用:VKA和DOAC之间有什么区别?
Francesco Alfano1,2, Anna Maria Gori1,2, Martina Berteotti1,2
1Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Biomedicines
|August 28, 2025
概括
与直接口服抗凝剂不同,维生素K对抗剂 (VKA) 可能会降低心房患者的炎症. 这表明抗凝剂对AF治疗中的炎症生物标志物有不同的作用.
科学领域:
- 心脏病学
- 炎症研究
- 药理学
背景情况:
- 前庭动 (AF) 是一种常见的心律失常,其发病因子包括炎症.
- 炎症在AF中的因果作用及其与潜在疾病的关系尚不清楚.
- 关于口服抗凝剂 (OACs) 如何影响AF中的促炎细胞因子的数据有限.
研究的目的:
- 研究维生素K对抗剂 (VKAs) 和直接口服抗凝剂 (DOACs) 对AF患者炎症生物标志物的差异作用.
- 探索抗凝剂治疗对调节与心房相关的炎症的作用.
主要方法:
- 这是一项前性,观察性,单中心研究.
- 分析了170名具有完整临床和生物幽默数据的老年AF患者.
- 使用多变量逻辑回归来评估高炎症水平的预测因素.
主要成果:
- VKA治疗与较低程度炎症的可能性独立相关 (OR = 0.26; p = 0.007).
- 即使抗炎细胞因子水平不平衡,也观察到这种保护作用.
- 初步证据表明VKAs与DOACs对IL-6和TNF-α等炎症生物标志物的差异调节.
结论:
- 结果表明VKA和DOAC可能对AF的炎症生物标志物产生不同的影响.
- 炎症生物标志物可能有助于预测AF中风风险.
- 这些结果产生了根据炎症特征量身定制的AF治疗策略的假设.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34


